No abstract available
MeSH terms
-
Alemtuzumab
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm / administration & dosage
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Carmustine
-
Cell Transformation, Neoplastic*
-
Cyclophosphamide / administration & dosage
-
Cytarabine
-
Doxorubicin / administration & dosage
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunotherapy, Adoptive* / methods
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
-
Lymphocyte Transfusion / methods
-
Melphalan
-
Podophyllotoxin
-
Prednisone / administration & dosage
-
Remission Induction / methods
-
Rituximab
-
Time Factors
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Cytarabine
-
Alemtuzumab
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Podophyllotoxin
-
Melphalan
-
Carmustine
-
Prednisone
Supplementary concepts
-
BEAM protocol
-
CHOP protocol